All In MedTech

Device Trial Radar · NCT01190306

Safety Study of the VEGA UV-A System to Treat Keratoconus

Safety and Effectiveness of the VEGA UV-A System for Corneal Collagen Cross-Linking in Eyes With Keratoconus

Last checked: Nov 20, 2026Latest source record: Jul 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 127 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

127

Actual

Start

Aug 2010

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Lead sponsor
Topcon Medical Systems, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 27, 2010

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL), when used to treat keratoconus.

Conditions

  • Keratoconus

Interventions

  • The VEGA UV-A Illumination SystemDevice

    This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area

  • RiboflavinDrug

    Riboflavin is a solution that will be delivered to the treatment area

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Corneal Curvature.Time frame: 6 Months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Barnet Dulaney Perkins Eye Center

    Phoenix, Arizona

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.